Publications

publications

Related publications from the „CYPtest group”:

Kiss Á, Tóth K, Juhász C, Temesvári M, Paulik J, Hirka G, Monostory K: Is CYP2D6 phenotype predictable from CYP2D6 genotype? Microchemical Journal 136: 209-214, 2018

Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K: Potential role of patients’ CYP3A-status in clozapine pharmacokinetics. International Journal of Neuropsychopharmacology 20: 529-537, 2017

Tóth K, Csukly G, Sirok D, Belic A, Háfra E, Kiss Á, Déri M, Menus Á, Bitter I, Monostory K: Optimization of clonazepam therapy adjusted to patient’s CYP3A-status and NAT2 genotype. International Journal of Neuropsychopharmacology 19: 1-9, 2016

Bűdi T, Tóth K, Nagy A, Szever Z, Kiss Á, Temesvári M, Háfra E, Garami M, Tapodi A, Monostory K: Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia., 56(6):849-55, 2015

Monostory K, Tóth K, Kiss Á, Háfra E, Csikány N, Paulik J, Sárváry E, Kóbori L: Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients. Br J Clin Pharmacol, 80(6):1429-37,2015

Tóth K, Bűdi T, Kiss Á, Temesvári M, Háfra E, Nagy A, Szever Z, Monostory K: Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy. Personalized Medicine, 12(3): 199-207,2015

Belic A, Tóth K, Vrzal R, Temesvári M, Porrogi P, Orbán E, Rozman D, Dvorak Z, Monostory K: Dehydroepiandrosterone post-transcriptionally modifies CYP1A2 induction involving androgen receptor. Chemico-Biological Interactions, 203: 597-603, 2013

Temesvári M, Kóbori L, Paulik J, Sárváry E, Belic A, Monostory K: Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. Journal of Pharmacology and Experimental Therapeutics 341: 294-305, 2012

Temesvári M, Paulik J, Kóbori L, Monostory K: High-resolution melting curve analysis to establish CYP2C19*2 single nucleotide polymorphism: comparison with hydrolysis SNP analysis. Molecular and Cellular Probes 25: 130-133, 2011

Monostory K, Dvorak Z: Steroid regulation of drug-metabolizing cytochromes P450. Current Drug Metabolism 12: 154-172, 2011

Rezen T, Rozman D, Pascussi J-M, Monostory K: Interplay between cholesterol and drug metabolism. Biochim Biophys Acta – Proteins and Proteomics 1814: 146-160, 2011

Rozman D, Monostory K: Perspectives of the non-statin hypolipidemic agents. Pharmacology and Therapeutics. 127: 19-40, 2010

Belic A, Temesvári M, Kőhalmy K, Vrzal R, Dvorak Z, Rozman D, Monostory K: Investigation of the CYP2C9 induction profile in human hepatocytes by combining experimental and modelling approaches. Current Drug Metabolism 10: 457-461, 2009

Monostory K, Pascussi J-M, Kóbori L, Dvorak Z: Hormonal regulation of CYP1A expression. Drug Metabolism Reviews 41: 547-572, 2009

Monostory K, Pascussi J-M, Szabó P, Temesvári M, Kőhalmy K, Acimovic J, Kocjan D, Kuzman D, Wilzewski B, Bernhardt R, Kóbori L, Rozman D: Drug-interaction potential of 2-((3,4-(dichlorophenethyl(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel non-statin type cholesterol lowering agent. Drug Metabolism and Disposition 37: 375-385, 2009

Kóbori L, Kőhalmy K, Porrogi P, Sárváry E, Gerlei Zs, Fazakas J, Nagy P, Járay J, Monostory K: Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism. British Journal of Clinical Pharmacology 65: 428-436, 2008

Kőhalmy K, Tamási V, Kóbori L, Sárváry E, Pascussi J-M, Porrogi P, Rozman D, Prough RA, Meyer UA, Monostory K: Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metabolism and Disposition 35: 1495-1501, 2007

Monostory K, Kőhalmy K, Prough, RA, Kóbori L, Vereczkey L: The effect of synthetic glucocorticoid, dexamethasone on CYP1A1 inducibility in adult rat and human hepatocytes. FEBS Letters 579: 229-235, 2005

Monostory K, Hazai E, Vereczkey L: Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chemico-Biological Interactions 147: 331-340, 2004

Szűcs G, Tamási V, Laczay P, Monostory K: Biochemical background of toxic interaction between tiamulin and monensin. Chemico-Biological Interactions 147: 151-161, 2004

Tamási V, Hazai E, Porsmyr-Palmertz M, Ingelman-Sundberg M, Vereczkey L, Monostory K: GYKI-47261, a new AMPA antagonist is a CYP2E1 inducer. Drug Metabolism and Disposition 31:1310-1314, 2003

Tamási V, Vereczkey L, Falus A, Monostory K: Some aspects of interindividual variations in the metabolism of xenobiotics. Inflammation Research 52:322-333, 2003

Hazai E, Vereczkey L, Monostory K: Reduction of toxic metabolite formation of acetaminophen. Biochemical Biophysical Research Communications 291: 1089-1094, 2002

Tamási V, Kiss Á, Dobozy O, Falus A, Vereczkey L, Monostory K: The effect of dexamethasone on P450 activities in regenerating liver. Biochemical Biophysical Research Communications 286: 239-242, 2001

Monostory K, Vereczkey L, Lévai F, Szatmári I: Iprifalvone as an inhibitor of human cytochrome P450 enzymes. British Journal of Pharmacology 123: 605-610, 1998

Monostory K, Jemnitz K, Vereczkey L, Czira G: Species differences in metabolism of panomifene, an analogue to tamoxifen. Drug Metabolism and Disposition 25: 1370-1378, 1997

Monostory K, Vereczkey L: The effect of phenobarbital and dexamethasone coadministration on the activity of rat liver P450 system. Biochemical Biophysical Research Commununications 203: 351-358, 1994